Panduan definitif tentang penyuntingan gen.
★
Menu
Beranda Pelajari Berita
Jelajahi Teknologi Penyakit Perawatan Uji Klinis Perusahaan Ilmuwan Gen-gen Penelitian Institusi
Di luar dunia medis Pertanian Etika Investasi Peta dunia
Pelajari & Alat Mulai di sini Glosarium A–Z Bandingkan teknologi Linimasa Daftar & Peringkat Agen AI ★ Tersimpan API
Tentang Tentang kami Metodologi Sumber Data Kebijakan Editorial Kontak Penafian

Tampilan Terpandu
Baru mengenal genetika? Kami menjelaskan setiap istilah saat kamu menjelajah, dalam bahasa yang mudah dipahami. Halaman yang sama, dengan bantuan yang sudah tersedia.

Pandangan Ahli
Kamu sudah mengenal biologinya. Cukup kontennya, ringkas dan padat, tanpa penjelasan tambahan. Ini adalah tampilan default.

Bahasa antarmuka
Mode terang
Zinc finger proteins binding along a DNA helix

Technology · Earlier generation

Zinc Finger Nucleases

The first programmable gene-editing tool to reach patients: small, engineered proteins that grip DNA in three-letter blocks.

Phase III DNAcuts DNAprotein-guidedcompact
Clinical research Being tested in people in registered clinical trials. Being in trials is not evidence that a treatment works or is safe.

Penjelasan sederhana

The original. Zinc fingers are small protein modules, each gripping about three letters of DNA, that can be chained together to recognise a longer sequence and joined to a cutting enzyme. They are difficult to design and they got there first: the earliest human gene-editing trials, more than a decade before CRISPR reached a patient, used zinc finger nucleases.

Pelajari lebih dalam

Zinc finger nucleases fuse arrays of Cys2-His2 zinc finger domains, each contacting roughly three base pairs, to the FokI nuclease domain, and are used in pairs. Their compact size is a genuine advantage for AAV delivery. Their weakness is design: context-dependent binding between adjacent fingers makes engineering an array for a chosen sequence difficult, which is precisely the problem CRISPR made irrelevant.

Historical importance

ZFNs carried gene editing into humans. Sangamo's SB-728-T programme disrupted CCR5 in T cells of people with HIV from 2009, establishing that a targeted, permanent edit could be made in a patient's cells and administered safely enough to continue. Every subsequent editing programme was built on regulatory ground that work broke.

They remain in clinical development, particularly where compact size aids delivery.

Sources

Connected in CRISPR Decoded

Every entry on this site is linked to the others it relates to. These connections are part of the record, not a search result.

Berita yang terkait dengan halaman ini

Dicocokkan secara otomatis dengan catatan ini. Setiap item tertaut ke penerbitnya.

Hanya informasi edukatif Halaman ini adalah referensi, bukan nasihat medis. Status riset dan regulasi dapat berubah; periksa tanggal pembaruan terakhir di atas dan konfirmasi hal-hal penting dengan sumber primer yang tercantum.